Italy-based EDC provider, Nubilaria srl, offers its ACTide EDC pro-bono for European non-profit COVID-19 Coronavirus related studies. The platform is made available for the agile collection of clinical data, remote patient monitoring and customizable collaborative process for the management of intensive therapies and relocation of patients according to hospital availability.

ACTide EDC is a validated, FDA 21 Part 11 compliant platform powered by its native drag & drop eCRFs Designer and modules including RTSM and ePRO.

ACTide serves 10000+ patients and 2000+ users in Italy and Europe. It's customer base ranges between doctors, caregivers, hospital pharmacists, logistic operators, CRO and Pharma.

Nubilaria pledges its maximum commitment possible toward a fast study deployment for all received requests. The offer applies only to public bodies and any other entity involved in non-profit research.

About Nubilaria & ACTide

Nubilaria® employs professionals with proven experience in the Clinical Data Management.

Thanks to the flexibility and the usability of its solutions, Nubilaria® has consolidated a network of Customers / Partners who trust its reliability and responsive support.

ACTide by Nubilaria® is the web-based platform suitable for any type of clinical trials, for human and veterinary studies, in a secure and validated environment.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.